Role of bone morphogenetic proteins in transitional cell carcinoma cells

Cancer Letters

Volumn 241, Issue 1, 2006, Pages 118-123

  Kim, Isaac Yi ^a   Kim, Seong Jin ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bladder TCC cell line; BMP receptor; Bone morphogenetic proteins (BMPs); Transitional cell carcinoma (TCC)

Indexed keywords

BONE MORPHOGENETIC PROTEIN;

BLADDER TUMOR; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE;

BONE MORPHOGENETIC PROTEINS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; HUMANS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 39049188065     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.10.009     Document Type: Article

References (57)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics. CA Cancer J. Clin. 2005, 55:10-30.
2. Raghavan D., Shipley W.U., Garnick M.B., Russell P.J., Richie J.P. Biology and management of bladder cancer. N. Engl. J. Med. 1990, 322:1129-1138.
3. Steinberg G., Bahnson R., Brosman S., Middleton R., Wajsman Z., Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J. Urol. 2000, 163:761-767.
4. Fontana D., Bellina M., Scoffone C., Cagnazzi E., Cappia S., Cavallo F., et al. Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur. Urol. 1996, 29:470-476.
5. Kroft S.H., Oyasu R. Urinary bladder cancer: mechanisms of development and progression. Lab. Invest. 1994, 71:158-174.
6. Nagata Y., Abe M., Kobayashi K., Saiki S., Kotake T., Yoshikawa K., et al. Point mutations of c-ras genes in human bladder cancer and kidney cancer. Jpn. J. Cancer Res. 1990, 81:22-27.
7. Kotake T., Saiki S., Kinouchi T., Shiku J., Nakayama E. Detection of the c-myc gene product in urinary bladder cancer. Jpn. J. Cancer Res. 1990, 81:1198-1201.
8. Lipponen P.K. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J. Pathol. 1995, 175:203-210.
9. Akiyama T., Sudo C., Ogawara H., Toyoshima K., Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986, 232:1644-1646.
10. Lee J., Dull T.J., Lax I., Schlessinger J., Ulrich A. HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. Eur. Mol. Biol. Org. J. 1989, 8:167-173.
11. Moriyama M., Akiyama T., Yamamoto T., Kawamoto T., Kato T., Sato K., et al. Expression of c-erbB-2 gene product in urinary bladder cancer. J. Urol. 1991, 145:423-427.
12. Underwood M., Bartlett J., Reeves J., Gardiner D.S., Scott R., Cooke T. C-erbB-2 gene amplification: molecular marker in recurrent bladder tumors?. Cancer Res. 1995, 55:2422-2430.
13. Lipponen P., Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer 1994, 69:1120-1125.
14. Mellon J.K., Lunec J., Wright C., Horne C.H., Kelly P., Neal D.E. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J. Urol. 1996, 155:321-326.
15. Cairns P., Shaw M.E., Knowles M.A. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993, 8:1083-1085.
16. Tokunaga H., Lee D.H., Kim I.Y., Wheeler T.M., Lerner S.P. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin. Cancer Res. 1999, 5:2520-2525.
17. Logothetis C.J., Xu H.J., Ro J.Y., Hu S.X., Sahin A., Ordonez N., Benedict W.F. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl Cancer Inst. 1992, 84:1256-1261.
18. Cordon-Cardo C., Wartinger D., Petrylak D., Dalbagni G., Fair W.R., Fuks Z., Reuter V.E. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst. 1992, 84:1251-1256.
19. Lipponen P.K. Overexpression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer 1993, 53:365-370.
20. Sarkis A.S., Dalbagni G., Cordon-Cardo C., Zhang Z.F., Sheinfeld J., Fair W.R., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst. 1993, 85:53-59.
21. Nguyen M., Watanabe H., Budson A.E., Richie J.P., Hayes D.F., Folkman J. Elevated levels of an angiogenic peptide basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl Cancer Inst. 1993, 85:241-242.
22. Crew J.P., O'Brien T., Bicknell R., Fuggle S., Cranston D., Harris A.L. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J. Urol. 1999, 161:799-804.
23. Grossfeld G.D., Ginsberg D.A., Stein J.P., Bochner B.H., Esrig D., Groshen S., et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl Cancer Inst. 1997, 89:219-227.
24. Gohji K., Fujimoto N., Ohkawa J., Fujii A., Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br. J. Cancer 1998, 77:650-655.
25. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
26. Sampath T.K., Maliakal J.C., Hauschka P.V., Jones W.K., Sasak H., Tucker R.F., et al. Recombinant human osteogenic protein-1 (OP-1) induces bone formation. J. Biol. Chem. 1992, 267:20352-20362.
27. Hogan B.L. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996, 10:1580-1594.
28. Zhao G.-Q. Consequences of knocking out BMP signaling in the mouse. Genesis 2003, 35:43-56.
29. Li F., Lu S., Vida L., Thomson J.A., Honig G.R. Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells in vitro. Blood 2001, 98:335-342.
30. Hager-theodorides A.L., Outram S.V., Shah D.K., Sacedon R., Shrimpton R.E., Vicente A., et al. Bone morphogenetic protein 2/4 signaling regulates early thymocyte differentiation. J. Immunol. 2002, 169:5496-5504.
31. Holley S.A., Neul J.L., Attisano J., Wrana J.L., Sasai Y., O'Connor M.B., et al. The xenopus dorsalizing factor noggin ventralizes drosophila embryos by preventing DPP from activation its receptors. Cell 1996, 86:607-617.
32. Piccolo S., Sasai Y., Lu B., De Robertis E.M. Dorsoventral patterning in xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell 1996, 589-598.
33. Liu F., Ventura F., Doody J., Massague J. Human type II receptor for bone morphogenetic proteins (BMPs); extension of the two-kinase receptor model to BMPs. Mol. Cell Biol. 1995, 15:3479-3486.
34. Miyazono K., Maedab S., Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005, 16:251-263.
35. Yamashita H., ten Dijke P., Heldin C.H., Miyazono K. Bone morphogenetic protein receptors. Bone 1996, 19:569-574.
36. Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H., ten Dijke P., et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl Acad. Sci. USA 1995, 92:7632-7636.
37. ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Esterez M., Riddle D.L., et al. Introduction of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J. Biol. Chem. 1994, 269:16985-16988.
38. Autzen P., Robson C.N., Bjartell A., Malcolm A.J., Johnson M.I., Neal D.E., Hamdy F.C. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer 1998, 78:1219-1223.
39. Masuda H., Fukabori Y., Nakano K., Takezawa Y., Suzuki T., Yamanaka H. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. The Prostate 2003, 54:268-274.
40. Kim I.Y., Lee D.-H., Ahn H.-J., Tokunaga H., Song W., Devereaux L.M., et al. Expression of bone morphogenetic protein receptors type-IA, -IB, and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res. 2000, 60:2840-2844.
41. Kim I.Y., Lee D.H., Ahn H.J., Kim M.M., Morton R.A. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23:7651-7659.
42. Helms M.W., Packeisen J., August C., Schittek B., Boecker W., Brandt B.H., Buerger H. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J. Pathol. 2005, 206:366-376.
43. Nosho K., Yamamoto H., Adachi Y., Endo T., Hinoda Y., Imai K. Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br. J. Cancer 2005, 92:1193-1200.
44. Yoshikawa H., Nakase T., Myoui A., Ueda T. Bone morphogenetic proteins in bone tumors. J. Orthop. Sci. 2004, 9:334-340.
45. Ide H., Yoshida T., Matsumoto N., Aoki K., Osada Y., Sugimura T., Terada M. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 1997, 57:5022-5027.
46. Brubaker K.D., Corey E., Brown L.G., Vessella R.L. Bone morphogenetic protein signaling in prostate cancer cell lines. J. Cell. Biochem. 2003, 91:151-160.
47. Miyazaki H., Watabe T., Kitamura T., Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 2004, 23:9326-9335.
48. Yang S., Zhong C., Frenkel B., Reddi A.H., Roy-Burman P. Diverse biological effect and smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res. 2005, 65:5769-5777.
49. Dai J., Keller J., Zhang J., Lu Y., Yao Z., Keller E.T. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005, 65:8274-8285.
50. Raida M., Clement J.H., Ameri K., Han C., Lee R.D., Harris A.L. Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int. J. Oncol. 2005, 26:1465-1470.
51. Langenfeld E.M., Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol. Cancer Res. 2004, 2:141-149.
52. Pouliot F., Blais A., Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res. 2003, 63:277-281.
53. Hallahan A.R., Pritchard J.I., Chandraratna R.A.S., Ellenbogen R.G., Geyer J.R., Overland R.P., et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat. Med. 2003, 9:1033-1038.
54. Kawamura C., Kizaki M., Ikeda Y. Bone morphogenetic protein (BMP-2) induces apoptosis in human myeloma cells. Leuk. Lymphoma 2002, 43:635-639.
55. Kim I.Y., Lee D.H., Lee D.K., Kim B.C., Kim H.T., Leach F.S., et al. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin. Cancer Res. 2003, 9:6046-6051.
56. Huang W., Rudkin G.H., Carlsen B., Ishida K., Ghasri P., Anvar B., et al. Overexpression of BMP-2 modulates morphology, growth, and gene expression in osteoblastic cells. Exp. Cell Res. 2002, 274:226-234.
57. Kim I.Y., Lee D.H., Lee D.K., Kim W.J., Kim M.M., Morton R.A., et al. Restoration of bone morphogenetic proteins receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line, TSU-Pr1. Cancer Res. 2004, 64:7355-7360.